BNGO übertreffen die 10 der letzten 29Schätzungen.
34%
Nächster Bericht
Datum des nächsten Berichts
30. März 2026
Estimate forQ4 25(Revenue/ EPS)
$7.94M
/
-$1.43
Implizierte Änderung vonQ3 25(Revenue/ EPS)
+7.81%
/
-10.06%
Implizierte Änderung vonQ4 24(Revenue/ EPS)
-2.71%
/
-90.97%
Bionano Genomics, Inc. Common Stock earnings per share and revenue
On 13. Nov. 2025, BNGO reported earnings of -1.59 USD per share (EPS) for Q3 25, beating the estimate of -1.94 USD, resulting in a 18.39% surprise. Revenue reached 7.37 million, compared to an expected 7.01 million, with a 5.12% difference. The market reacted with a +3.40% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analysts forecast an EPS of -1.43 USD, with revenue projected to reach 7.94 million USD, implying an decrease of -10.06% EPS, and increase of 7.81% in Revenue from the last quarter.
FAQ
What were Bionano Genomics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Bionano Genomics, Inc. Common Stock reported EPS of -$1.59, beating estimates by 18.39%, and revenue of $7.37M, 5.12% above expectations.
How did the market react to Bionano Genomics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 3.4%, changed from $1.47 before the earnings release to $1.52 the day after.
When is Bionano Genomics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 30. März 2026.
What are the forecasts for Bionano Genomics, Inc. Common Stock's next earnings report?
Based on 5
analysts, Bionano Genomics, Inc. Common Stock is expected to report EPS of -$1.43 and revenue of $7.94M for Q4 2025.